Depo-Provera has been a scientific and political battleground for over twenty years. At stake have been the reproductive health of women, the marketing of a long-acting contraceptive by a multinational corporation, and international family planning and population control. Seventy nations have approved its use as a female contraceptive, but the U.S. Food and Drug Administration (FDA) has not, because the drug is a suspected carcinogen. FDA's decision means marketing of Depo-Provera as a contraceptive is forbidden in the United States and in U.S. foreign aid programs. FDA's decision also means the drug is less likely to be used in Third World family planning programs.
Food, Drug. Cosmetic Law Journal, Vol. 42 (October 1987), 567-587.